13th Aug 2025 09:57
(Alliance News) - Glanbia PLC on Wednesday raised its earnings outlook reflecting expectations of further growth in the second half of 2025 across the business.
The Kilkenny, Ireland-based sports nutrition company now expects group adjusted earnings per share in the range of 130 to 133 euro cents, up from 124 to 130 cents previously. In 2024, the firm reported adjusted EPS of 140.03 cents.
Revenue growth in Performance Nutrition, excluding SlimFast and Body & Fit, is seen between 2% to 3%, previously in line with 2024, and Health & Nutrition earnings before interest, tax, depreciation and amortisation margin in the range of 18% to 19%, previously 17% to 18%.
"The category trends remain positive, and we expect to see continued improvement in volumes" across Performance Nutrition in the second half of the year with continued momentum in Health & Nutrition and Dairy Nutrition, the firm said in a statement.
In response, shares in the company jumped 13% to EUR13.79 each in London on Wednesday morning.
Pretax profit fell 33% to USD114.5 million in the first six months of 2025 from USD169.7 million a year prior. This included USD40.2 million of exceptional charges, mainly due to a restructuring at the firm,
compared to USD11.2 million a year ago.
Revenue climbed 6.0% to USD1.93 billion from USD1.82 billion, with volume growth of 0.9%, pricing up 3.4% and a 1.7% boost from acquisitions.
By division, revenue declined 3.8% in Performance Nutrition, rose 18% in Health & Nutrition and increased 14% in Dairy Nutrition.
"First half results were driven by volume growth, earnings and margin progression in H&N and DN, reflecting strong customer demand. This was offset by anticipated reduced performance in PN primarily as a result of elevated whey costs during the period," commented Chief Executive Hugh McGuire.
The interim dividend was raised 10% to 17.20 cents from 15.64 cents.
Alongside results, Glanbia announced the acquisition of Sweetmix, a Brazil-based nutritional premix and ingredients solutions business within the H&N division.
In addition Glanbia named Independent Non-Executive Director, Paul Duffy, as chair designate. He will succeed Donard Gaynor on January 1, 2026. Gaynor will retire as chair and from the board at the end of 2025.
By Jeremy Cutler, Alliance News reporter
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Glanbia